Obstructive sleep apnea (OSA) is associated with an increased risk of pulmonary hypertension in people with scleroderma, a study suggests.
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration has granted orphan drug designation to Theraly Fibrosis’ TLY012 for the treatment…
With the World Scleroderma Foundation (WSF)’s support, experts worldwide answered questions in the form of  recommendations for scleroderma…
Heart and kidney imaging may help detect fibrosis, or scarring, in asymptomatic people with scleroderma, and could be useful in…
One year of treatment with Tracleer (bosentan) significantly reduces the severity of patient-reported skin symptoms in people with…
The types of autoantibodies a person has are a better predictor of scleroderma prognosis than whether the person has other…
Scleroderma patients who develop digital ulcers are more likely to be younger at disease onset, male, and have…
The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to…
About a third of people diagnosed with scleroderma in the U.S. were prescribed immunosuppressive therapies in the first…
Treatment with Letairis (ambrisentan) failed to significantly reduce pulmonary blood pressure at rest and during exercise compared with…